norfloxacin has been researched along with Cholera in 7 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Cholera: An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An open randomised controlled clinical trial with 160 adults with acute watery diarrhoea and severe dehydration compared the efficacy of varying regimens of norfloxacin and doxycycline for the treatment of cholera caused by Vibrio cholerae 0139 Bengal." | 9.08 | Efficacy of norfloxacin and doxycycline for treatment of vibrio cholerae 0139 infection. ( Bhattacharya, MK; Bhattacharya, SK; Deb, A; Deb, M; Dutta, D; Manna, B; Moitra, A; Mukhopadhyay, AK; Nair, GB, 1996) |
| "Norfloxacin was superior to TMP-SMX and to the placebo in reducing stool output, duration of diarrhea, fluid requirements, and vibrio excretion." | 6.67 | Double-blind, randomized, controlled clinical trial of norfloxacin for cholera. ( Bhattacharya, MK; Bhattacharya, SK; De, SP; Dutta, A; Dutta, D; Dutta, P; Maitra, A; Pal, SC; Sikdar, SN, 1990) |
| " cholera were as follows 76% [67,84] to furazolidone, 65% [29,94] to nitrofurantoin, 55% [44,66] to nalidixic acid, 10% [2,23] to rifampicin, 4%(0, 12) to novobiocin, 4% [2,6] to norfloxacin, 3% [1,4] to ciprofloxacin, 1%(0, 3) to sparofloxacin, 0%(0, 3) to levofloxacin, 0%(0, 2) to ofloxacin, 0%(0, 0) to gatifloxacin." | 5.22 | Globally Vibrio cholera antibiotics resistance to RNA and DNA effective antibiotics: A systematic review and meta-analysis. ( Ebrahimzadeh, F; Gholami, S; Jafari-Sales, A; Rostami, A; Zadeh, FA, 2022) |
| "An open randomised controlled clinical trial with 160 adults with acute watery diarrhoea and severe dehydration compared the efficacy of varying regimens of norfloxacin and doxycycline for the treatment of cholera caused by Vibrio cholerae 0139 Bengal." | 5.08 | Efficacy of norfloxacin and doxycycline for treatment of vibrio cholerae 0139 infection. ( Bhattacharya, MK; Bhattacharya, SK; Deb, A; Deb, M; Dutta, D; Manna, B; Moitra, A; Mukhopadhyay, AK; Nair, GB, 1996) |
| "Norfloxacin was superior to TMP-SMX and to the placebo in reducing stool output, duration of diarrhea, fluid requirements, and vibrio excretion." | 2.67 | Double-blind, randomized, controlled clinical trial of norfloxacin for cholera. ( Bhattacharya, MK; Bhattacharya, SK; De, SP; Dutta, A; Dutta, D; Dutta, P; Maitra, A; Pal, SC; Sikdar, SN, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Rostami, A | 1 |
| Zadeh, FA | 1 |
| Ebrahimzadeh, F | 1 |
| Jafari-Sales, A | 1 |
| Gholami, S | 1 |
| Krishna, BV | 1 |
| Patil, AB | 1 |
| Chandrasekhar, MR | 1 |
| Chakrabarti, MK | 1 |
| Bhattacharya, MK | 4 |
| Sinha, AK | 1 |
| Chatterjee, DC | 1 |
| Bhattacharya, SK | 4 |
| Dutta, D | 2 |
| Deb, A | 2 |
| Deb, M | 1 |
| Manna, B | 1 |
| Moitra, A | 1 |
| Mukhopadhyay, AK | 2 |
| Nair, GB | 1 |
| Moolasart, P | 1 |
| Eampokalap, B | 1 |
| Supaswadikul, S | 1 |
| Ghosh, S | 1 |
| Dutta, P | 1 |
| De, SP | 1 |
| Sikdar, SN | 1 |
| Maitra, A | 1 |
| Dutta, A | 1 |
| Pal, SC | 1 |
1 review available for norfloxacin and Cholera
| Article | Year |
|---|---|
Globally Vibrio cholera antibiotics resistance to RNA and DNA effective antibiotics: A systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Cephalothin; Cholera; Cholera Toxin; Ciprofloxacin; Drug Resistance, Bacteria | 2022 |
3 trials available for norfloxacin and Cholera
| Article | Year |
|---|---|
Efficacy of norfloxacin and doxycycline for treatment of vibrio cholerae 0139 infection.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Cholera; Doxycycline; Humans; Male; Middle Aged | 1996 |
Comparison of the efficacy of tetracycline and norfloxacin in the treatment of acute severe watery diarrhea.
Topics: Adolescent; Adult; Age Factors; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Child; Child, Pr | 1998 |
Double-blind, randomized, controlled clinical trial of norfloxacin for cholera.
Topics: Adult; Cholera; Double-Blind Method; Feces; Humans; Male; Norfloxacin; Randomized Controlled Trials | 1990 |
3 other studies available for norfloxacin and Cholera
| Article | Year |
|---|---|
Fluoroquinolone-resistant Vibrio cholerae isolated during a cholera outbreak in India.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Child; Child, Preschool; Cholera; Ciprofloxacin; Dis | 2006 |
Evaluation of the efficacy of different antibiotics in inhibiting colonisation of Vibrio cholerae O1 in the rabbit intestine.
Topics: Animals; Anti-Bacterial Agents; Cholera; Ciprofloxacin; Disease Models, Animal; Evaluation Studies a | 1993 |
Outbreak of cholera caused by Vibrio cholerae 01 intermediately resistant to norfloxacin at Malda, West Bengal.
Topics: Adult; Age Distribution; Cholera; Developing Countries; Disease Outbreaks; Drug Resistance, Microbia | 2000 |